

# Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes

Chelsea C. Pinnix,<sup>1,2</sup> John T. Lee,<sup>1</sup> Zhao-Jun Liu,<sup>1</sup> Ronan McDaid,<sup>1</sup> Klara Balint,<sup>1</sup> Levi J. Beverly,<sup>1</sup> Patricia A. Brafford,<sup>1</sup> Min Xiao,<sup>1</sup> Benjamin Himes,<sup>1</sup> Susan E. Zabierowski,<sup>1</sup> Yumi Yashiro-Ohtani,<sup>4</sup> Katherine L. Nathanson,<sup>3</sup> Ana Bengston,<sup>5</sup> Pamela M. Pollock,<sup>5</sup> Ashani T. Weeraratna,<sup>6</sup> Brian J. Nickoloff,<sup>7</sup> Warren S. Pear,<sup>1</sup> Anthony J. Capobianco,<sup>1</sup> and Meenhard Herlyn<sup>1</sup>

<sup>1</sup>Wistar Institute; <sup>2</sup>University of Pennsylvania School of Medicine; Departments of <sup>3</sup>Medicine and <sup>4</sup>Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania; <sup>5</sup>Translational Genomics Research Institute, Phoenix, Arizona; <sup>6</sup>National Institute on Aging, NIH, Baltimore, Maryland; and <sup>7</sup>Department of Pathology, Loyola University Medical Center, Maywood, Illinois

## Abstract

**The importance of mitogen-activated protein kinase signaling in melanoma is underscored by the prevalence of activating mutations in N-Ras and B-Raf, yet clinical development of inhibitors of this pathway has been largely ineffective, suggesting that alternative oncogenes may also promote melanoma. Notch is an interesting candidate that has only been correlated with melanoma development and progression; a thorough assessment of tumor-initiating effects of activated Notch on human melanocytes would clarify the mounting correlative evidence and perhaps identify a novel target for an otherwise untreatable disease. Analysis of a substantial panel of cell lines and patient lesions showed that Notch activity is significantly higher in melanomas than their nontransformed counterparts. The use of a constitutively active, truncated Notch transgene construct (N<sup>IC</sup>) was exploited to determine if Notch activation is a “driving” event in melanocytic transformation or instead a “passenger” event associated with melanoma progression. N<sup>IC</sup>-infected melanocytes displayed increased proliferative capacity and biological features more reminiscent of melanoma, such as dysregulated cell adhesion and migration. Gene expression analyses supported these observations and aided in the identification of MCAM, an adhesion molecule associated with acquisition of the malignant phenotype, as a direct target of Notch transactivation. N<sup>IC</sup>-positive melanocytes grew at clonal density, proliferated in limiting media conditions, and also exhibited anchorage-independent growth, suggesting that Notch alone is a transforming oncogene in human melanocytes, a phenomenon not previously described for any melanoma oncogene. This new information yields valuable insight into the basic epidemiology of melanoma and launches a realm of possibilities for drug intervention in this deadly disease.** [Cancer Res 2009;69(13):5312–20]

## Introduction

The Notch signaling pathway is an evolutionarily conserved signaling cascade that affects cell fate decisions and many

differentiation processes during both embryonic and postnatal development (1). Notch signaling has also been implicated in neoplastic malignancies; a potential role for aberrant Notch signaling was first observed in T-cell acute lymphoblastic leukemia (T-ALL), wherein a chromosomal translocation resulted in the liberation of a truncated and constitutively activated form of the Notch1 receptor (N<sup>IC</sup>; ref. 2). Since this original report, the link of the Notch signaling pathway to tumorigenesis has been well established. Aberrant Notch signaling has been linked to prostate carcinoma (3), mouse mammary epithelial cell tumors (4), small cell lung cancer (5), neuroblastoma (6), cervical carcinoma (7), and most recently Kaposi's sarcoma (8). Activated Notch can transform primary Schwann cells (9) and, in collaboration with the adenovirus E1a protein, cultured rat embryonic epithelial cells (10).

Metastatic melanoma is a highly invasive tumor derived from epidermal melanocytes that is refractory to most therapies. Melanocytes are melanin-producing cells that reside along the basement membrane in the basal layer of the epidermis interspersed among surrounding keratinocytes. Keratinocytes, in turn, play a major role in regulating the growth and differentiation of melanocytes. Under normal conditions, E-cadherin is expressed on the surface of both melanocytes and keratinocytes and is the critical cell adhesion protein between these two cell types in the human epidermis (11, 12). Loss of E-cadherin expression is a well-documented step in melanoma development and progression (13–15). Conversely, up-regulation of other cell adhesion molecules, such as MCAM (MelCAM, MUC18, CD146), N-cadherin, and  $\alpha_v\beta_3$  integrins, have been strongly correlated with melanoma progression and metastasis (16–19). Expression of MCAM, a highly glycosylated membrane protein, confers metastatic potential in experimental murine models to MCAM-negative melanoma cells (18, 20).

Recent data suggest that Notch activation may play a role in melanoma progression. We have previously shown that activation of Notch signaling promotes the progression of early-stage melanoma cell lines in a  $\beta$ -catenin-dependent manner both *in vitro* and *in vivo* (21). Furthermore, microarray profiling comparing the gene expression of normal human melanocytes to human melanomas revealed up-regulation of Notch target genes in melanoma cells, suggesting activation of the Notch signaling pathway in melanoma (22). Based on these observations, we sought to determine the effects of Notch activation on primary human melanocytes. The data described herein define an oncogenic role for Notch signaling in melanocytes and highlight the potential for Notch inhibition to be used as a therapeutic approach for the treatment of melanoma.

**Note:** Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

**Requests for reprints:** Meenhard Herlyn, Wistar Institute, 3601 Spruce Street, Room 489, Philadelphia, PA 19104. Phone: 215-898-3950; Fax: 215-898-0980; E-mail: herlynm@wistar.org.

©2009 American Association for Cancer Research.  
doi:10.1158/0008-5472.CAN-08-3767




**Statistical analyses.** Data (from triplicate experiments) are presented as mean  $\pm$  SD and were analyzed by two-tailed Student's *t* test. A *P* value of  $<0.05$  was considered significant.

## Results


**The Notch signaling pathway is activated in human melanoma compared with primary human melanocytes.** To assess the potential role of Notch signaling in human melanocytic transformation, the activation status of the Notch pathway was assayed through several approaches. Using an antibody against activated Notch1, immunohistochemical staining was performed on the samples of melanoma patients (Fig. 1A). Active Notch1 staining colocalized with that of HMB45, a marker for cells of melanocytic origin. Normal tissues immediately adjacent to the lesion did not stain positively for active Notch1 (Fig. 1A, far right). Quantitative RT-PCR was performed on RNA from fresh melanoma lesions and established cell lines to determine levels of Notch1

expression (Fig. 1B); from 9 lesions and 14 cell lines, every sample tested expressed at least 5-fold more Notch1 than the representative primary human melanocytic control. The expression of Notch target genes in laser-microdissected melanoma lesions, melanoma cell lines, and melanocyte cell lines showed that Hes1 and Hey1, but not Hey2, were dramatically up-regulated in both melanoma tissue and cell lines when compared with primary melanocytes (Fig. 1C, top). Microarray analyses on a panel of melanoma cell lines displayed similar patterns of gene expression (Fig. 1C, bottom). RT-PCR analysis confirmed these data, as Notch-target transcripts were elevated in melanoma lines when compared with melanocytes (data not shown). Immunoblots depicted absent or low levels of the activated Notch1 protein in melanocytes but higher levels in melanoma lines, suggesting that the Notch signaling pathway is only active in malignant cells (Fig. 1D).

**Mechanism of Notch activation in melanoma.** Based on the endogenous overexpression of active Notch1 protein in melanoma tissue and cell lines, melanoma cell lines were screened in search of



**Figure 2.** Inhibition of Notch signaling suppresses melanoma but not melanocyte growth *in vitro*. *A*, expression of DN-MAML protein in melanoma cell line WM 3248 was detected by immunoblotting for the myc-tagged DN-MAML. Effect of DN-MAML expression on Notch1 targets Hes1, Hey1, and Hey2 was determined by quantitative RT-PCR in two melanoma cell lines, WM3248 and WM1366. *B*, 7-d growth curves of melanocytes and melanoma cells infected with DN-MAML or GFP lentiviruses. \*, *P* < 0.05 (Student's *t* test). *C*, growth inhibition in melanocytes and melanoma cells in the presence of increasing concentrations of a  $\gamma$ -secretase inhibitor. Cell growth was determined by MTT analysis. Results are percentage of growth inhibition compared with untreated controls (adjusted to 0%). \*, *P* < 0.005 (Student's *t* test).



**Figure 3.** Constitutive activation of the Notch1 pathway enhances melanocyte growth *in vitro*. *A*, left, mRNA analysis of Notch1 expression in GFP-infected and N<sup>1C</sup>-infected FOM 117 cells by RT-PCR; right, Western blot analysis of Notch1 protein expression in GFP and N<sup>1C</sup>-infected FOM 117 cells. *B*, immunofluorescence analysis of N<sup>1C</sup> localization in FOM 117 GFP and N<sup>1C</sup>-infected cells. *C*, mRNA expression of Hey1 and Hey2 in FOM 117 GFP and N<sup>1C</sup>-infected cells as determined by quantitative RT-PCR. *D*, ~2-wk growth curve of GFP-infected and N<sup>1C</sup>-infected FOM 123 and 124 cells. \*,  $P < 0.005$  (Student's *t* test).

activating mutations within the Notch1 locus similar to those reported in at least 50% of T-ALLs (23). Seventeen human melanoma and three T-ALL cell lines were sequenced within exon 26 (heterodimerizations; HD-N1, HD-N2, and HD-C) and exon 34 (transcriptional activation domain and PEST domain) of Notch1. Although no activating Notch1 genetic alterations were identified in the melanomas, insertional and missense mutations were confirmed in the three T-ALL cell lines (Supplementary Fig. S1). Approximately, 70% of the melanoma cell lines displayed the T allele of the C/T SNP previously reported at nucleotide 5097 (23). Despite the absence of Notch1 activating mutations in the melanoma cell lines tested, dramatic up-regulation of the Notch1 transcript was detected by real-time RT-PCR in 14 melanoma cell lines and 9 fresh tumor specimens, but not normal melanocytes (Fig. 1B), suggesting that the mechanism for enhanced Notch activation in melanoma may be due to Notch overexpression. Melanoma tumor specimens and cell lines showed significantly higher levels of Notch1 expression, with an average of 7.9-fold and 37.8-fold increase over a representative melanocyte cell line HEMN, respectively. The levels of Notch2/4 transcripts were also robustly up-regulated in melanoma lesions and cell lines (Supplementary Fig. S2).

#### Inhibition of Notch1 activity elicits antimelanoma activities.

The data, thus far, suggested strong Notch activation in melanoma; therefore, the effects of Notch inhibition on melanocyte and


melanoma growth were tested *in vitro*. To suppress the Notch signaling cascade, a dominant-negative mutant of the Mastermind-like (MAML) protein was used. This construct acts as a pan-Notch inhibitor and prevents transcription of downstream target genes by binding to N<sup>1C</sup> and preventing the recruitment of coactivator proteins to the Notch enhanceosome. The myc-tagged DN-MAML vector was lentivirally infected into two melanocyte cell lines and two melanoma cell lines. After selection, these lines were analyzed for DN-MAML expression by probing for the myc tag (Fig. 2A, top). Quantitative RT-PCR analysis of Hey1 and Hey2 revealed suppression of these Notch targets in DN-MAML-infected melanoma cell lines. Hes1 levels were initially low and generally unaffected by DN-MAML expression (Fig. 2A, bottom). As depicted in Fig. 2B, the growth rate of DN-MAML-infected melanoma cell lines was significantly reduced when compared with green fluorescent protein (GFP)-expressing cells but was unaffected in two primary melanocyte cell lines. Consistent with these data, suppression of Notch signaling activation through pharmacologic inhibition selectively decreased the growth of melanoma cell lines, but not melanocytes, in a dose-dependent manner (Fig. 2C). A  $\gamma$ -secretase inhibitor, GSI X, at the highest concentration of 5  $\mu$ mol/L inhibited melanoma growth by as much as 32%, as determined by MTT analysis. These results are compatible with a previous work indicating that  $\gamma$ -secretase inhibitors preferentially decrease the growth of human melanoma cells, but not melanocytes (26).

**Expression of human activated Notch1 ( $N^{1C}$ ) in human melanocytes.** Based on the above data, the potential role of Notch signaling in melanocyte transformation and melanoma development was investigated. To determine the effects of active Notch1 expression in primary human melanocytes, the  $N^{1C}$  gene was introduced into primary human melanocytes. First, lentiviral vectors encoding either GFP or  $N^{1C}$ -GFP were used for stable intracellular expression of  $N^{1C}$ . To verify expression of the lentiviral-derived  $N^{1C}$ , Notch1 mRNA and protein expression was assessed via semiquantitative RT-PCR and Western blotting (Fig. 3A). Immunofluorescence of GFP and  $N^{1C}$ -infected melanocytes was performed with a Notch1 antibody to assess the localization of the lentiviral-derived construct (Fig. 3B).  $N^{1C}$  protein was appropriately detected in the nucleus and was also capable of activating expression of downstream Notch1 target genes, as evidenced by increased expression of the Notch-regulated genes *Hey1* and *Hey2* (Fig. 3C).

Because the  $N^{1C}$  oncoprotein has been shown previously to promote cellular growth (27, 28), the effects of constitutive Notch1 activation on primary melanocyte growth were ascertained *in vitro*. The growth rate of  $N^{1C}$ -infected melanocytes was significantly


increased compared with that of corresponding GFP control cells (Fig. 3D). Collectively, the data suggest that Notch is activated in melanoma and that this is sufficient to increase melanocytic growth *in vitro*.

**Activated Notch1 promotes cytoskeletal changes, increased adhesion, and migration in primary human melanocytes.** In addition to increased growth rates, at 72 to 96 hours postinfection,  $N^{1C}$ -expressing melanocytes exhibited marked morphologic changes compared with GFP (Fig. 4A) or uninfected parental controls (data not shown). The cells exhibited shorter dendrites, grew in large clusters, and formed endothelial-like networks reminiscent of vasculogenic mimicry (29). These changes were consistent across all six melanocyte lines infected with the  $N^{1C}$  lentivirus. In addition to these morphologic changes, the  $N^{1C}$  transgene promoted increased adhesion in melanocytes (Fig. 4B). Lastly, migration assays using Boyden chambers showed that  $N^{1C}$ -infected melanocytes possess increased invasive capacity compared with GFP-infected controls (Fig. 4C and D). Each of these biological properties supports a role for Notch activity in acquisition of a malignant phenotype, although the downstream



**Figure 4.** Constitutive Notch1 activation induces cytoskeletal, adhesion, and migratory changes in primary melanocytes. *A*, phalloidin immunostaining reveals morphologic changes induced by active Notch1 expression. FOM 123 and 124  $N^{1C}$  cells form networks of capillary-like structures when grown in monolayer compared with the normal dendritic growth pattern of normal GFP-infected cells. *B*, cell adhesion assay showed that  $N^{1C}$ -infected FOM cells possess increased adhesive properties compared with GFP-infected controls within 2 h postplating. \*,  $P < 0.005$  (Student's *t* test). *C* and *D*,  $N^{1C}$ -infected and GFP-infected melanocytes were subject to Boyden chamber assays to test their ability to migrate through Matrigel. After 24 h, membranes stained with 4',6-diamidino-2-phenylindole (DAPI) showed enhanced ability of  $N^{1C}$ -infected FOM cells to migrate; 1205Lu melanoma cells acted as a positive control.

**Figure 5.** Identification of a CSL binding sequence within the human MCAM promoter. *A*, immunoblot analysis of E-cadherin, MCAM,  $\beta$ 3-integrin, and active Notch1 protein levels in primary melanocytes infected with GFP (G) or  $N^{IC}$  (N) lentiviruses. *B*, FOM 117 melanocytes were plated on Jagged1-Fc or control Fc plates for 72 h and subsequently assayed for active Notch1 and MCAM expression by immunoblotting. *C*, enhanced MCAM protein expression in  $N^{IC}$ -infected WM 3248 melanoma cells (*left*). Interruption of Notch signaling by treatment with 5  $\mu$ mol/L GSI  $\times$  decreased MCAM expression in uninfected WM 3248 cells, as determined by immunoblotting for MCAM (*right*). *D*, *top*, multiple consensus binding sequences for CSL, the hexamer TGGGAA, were identified within the human MCAM promoter at positions  $-477$  and  $-3500$  (see text for details); *bottom*, ChIP analysis showing association of CSL with regions of the MCAM promoter. Hes1 acts as a positive control for binding activity, whereas MCAM  $-1.5$  K is a negative control.



effector molecules of Notch1, which may contribute to the observed phenotypes, are uncertain.


**Identification of MCAM as a target of Notch signaling in melanocytes.** Microarray analyses were performed to aid in the identification of genes differentially expressed between Notch-infected and control melanocytes [microarray data is available at GEO (GSE15040)]. Using GeneSpring software gene ontology classification analysis, subgroups with specified biological functions were identified, including those within cell adhesion and invasion families; a small fraction of those genes are depicted in Supplementary Table S1. Notably, MCAM, an important mediator of melanoma progression, was significantly up-regulated in  $N^{IC}$ -infected cells, as well as the N-cadherin (CDH2; ref. 24).

Quantitative RT-PCR was performed on a panel of genes selected from the gene ontology groups to confirm the observed changes in gene expression (data not shown). Of these, E-cadherin and MCAM were differentially expressed and, therefore, chosen for further analysis because loss of E-cadherin and up-regulation of MCAM expression are well-characterized events in melanoma development and progression. Immunoblotting analyses showed that  $N^{IC}$  expression induced robust up-regulation of MCAM and down-regulation of E-cadherin in the melanocyte cells (Fig. 5A). The gene expression changes induced by  $N^{IC}$  are consistent with a shift toward a malignant phenotype. Expression levels of  $\beta$ 3 integrin, another adhesion protein implicated in melanoma development

and progression, however was unaffected by  $N^{IC}$  overexpression (Fig. 5A).

**MCAM is a direct Notch1 target.** To begin to test the hypothesis that MCAM is a direct Notch target, melanocytes were plated on tissue culture dishes anchored with Jagged-1 to induce ligand-mediated Notch activation. Cell extracts confirmed that MCAM expression was induced in response to Notch activation, indicating that MCAM up-regulation can occur through induction of endogenous Notch1 receptor activity (Fig. 5B). Moreover, in an MCAM-expressing melanoma cell line, WM 3248, inhibition of Notch activation with a  $\gamma$ -secretase inhibitor suppressed MCAM expression; likewise, expression of  $N^{IC}$  increased MCAM levels, as predicted (Fig. 5C). Knockdown of MCAM in  $N^{IC}$ -expressing melanocytes had no bearing on their ability to grow in soft agar, suggesting that up-regulation of MCAM in this system is a contributory, rather than an initiating event in melanomagenesis (data not shown).

Based on the robust up-regulation of MCAM in  $N^{IC}$ -expressing melanocytes, we sought to further define the mechanism of MCAM induction. Multiple CSL/Notch-binding sequences were identified within the MCAM promoter, including a nonconserved sequence at  $-477$ , as well as three conserved sites in the proximity of  $-3.5$ K ( $-3487$ ,  $-3510$ , and  $-3522$ ; Fig. 5D, *top*). The consensus motif, hexamer TGGGAA, has been shown to bind CSL (30) and is present in the human p21 promoter (31), the murine Hes1 promoter (32),



**Figure 6.** Notch1 activation transforms primary melanocytes *in vitro*. **A**, constitutive Notch1 activation induces focus formation in N<sup>1C</sup>-infected melanocytes grown in monolayer on tissue culture dishes. \*,  $P < 0.005$  (Student's *t* test). **B**, N<sup>1C</sup>-infected melanocytes display increased survival in limiting growth factor conditions, as depicted: 100% media indicate normal melanocytes media containing bFGF, SCF, and ET3; 10% media is a 10-fold decrease in fetal bovine serum. The growth factor(s) present in each respective medium is described beneath each panel. \*,  $P < 0.005$  (Student's *t* test). **C**, N<sup>1C</sup>-infected melanocytes display anchorage-independent growth in soft agar. \*,  $P < 0.005$  (Student's *t* test).

and the human Skp2 promoter (33). ChIP assays showed that N<sup>1C</sup> strongly enhanced CSL binding at the conserved -3500 sites on the MCAM promoter. The nonconserved sequence at -477, however, yielded less binding (Fig. 5D, bottom). The results from ChIP assays were subsequently confirmed through electrophoretic mobility shift assay analysis (data not shown). Together, these data underscore a direct role for Notch in the up-regulation of MCAM and, likely, disease progression.

**N<sup>1C</sup> confers transforming properties to melanocytes *in vitro*.** Loss of contact inhibition is a common phenotype of transformed cells. After selection, N<sup>1C</sup>-infected cells formed discrete foci, whereas GFP control cells did not (Fig. 6A). These foci were adherent and viable, as determined by trypan blue exclusion (data not shown). The changes in cellular morphology and the loss of contact inhibition in N<sup>1C</sup>-transduced melanocytes were reminiscent of transformed cells. In addition, GFP-infected and N<sup>1C</sup>-infected cells were plated, and their survival was assayed over the span of 72 hours in limiting media conditions (Fig. 6B). N<sup>1C</sup>-infected cells

display enhanced survival in media conditions that otherwise kill normal human melanocytes.

Anchorage-independent growth is a hallmark of malignant cell transformation that highly correlates with neoplasia; thus, anchorage-independent colony-forming capacity of GFP and N<sup>1C</sup>-infected melanocytes was analyzed. After plating GFP and N<sup>1C</sup>-infected melanocytes in soft agar with normal melanocyte media, GFP cells failed to establish viable colonies whereas N<sup>1C</sup>-infected cells readily formed colonies (Fig. 6C). To assess neoplastic transformation potential *in vivo*,  $2 \times 10^6$  GFP or N<sup>1C</sup>-expressing melanocytes were injected s.c. into NOD-SCID mice. Twelve weeks postinjection, tumors were not detected (data not shown), suggesting that additional genetic events may be required to achieve growth in animal models.

## Discussion

Here, we show that Notch1 signaling is activated in melanoma cells, but not melanocytes, and that constitutive Notch1 activation

confers transforming properties to primary melanocytes *in vitro*. Notch receptors 1, 2, and 4 are overexpressed in melanoma cell lines and lesions, particularly when compared against primary melanocytes or normal human skin. Notch and Notch target genes are up-regulated in both melanoma lesions and melanoma cell lines. Ectopic N<sup>IC</sup> expression induced gross morphologic changes, increased growth, adhesion, migration, and survival, and resulted in the loss of E-cadherin expression and up-regulation of MCAM, two well-characterized events in melanoma development. We identify MCAM as a direct Notch target due to the presence of two high-affinity CSL binding sites present in the MCAM promoter. The N<sup>IC</sup> oncoprotein conferred anchorage-independent growth, increased survival, and loss of contact inhibition; suppression of Notch signaling decreased the growth of melanoma cell lines, whereas primary melanocytes were unaffected. Taken together, these data suggest that deregulation of Notch signaling plays a specific role in promoting a transformed phenotype in human melanocytes and define the importance of Notch signaling in human melanoma.

Our microarray data describing Notch pathway activity is underscored by a recent report by Hoek and colleagues that revealed up-regulation of Notch2 and Hey1 in a separate but distinct panel of malignant melanoma cell lines, suggesting a role for Notch activation in the transformation of melanocytes (22). Previous immunohistochemical studies on early-phase melanoma lesions have shown overexpression of full-length Notch1 protein in melanoma tissue compared against benign human nevi (21) and normal human skin (8). In our current study, we examined active Notch1 levels and found overexpression of this protein by immunohistochemical analysis of paraffin-embedded melanoma lesions and Western blotting of melanoma cell lines. Furthermore, suppression of Notch signaling via a dominant-negative MAML construct or  $\gamma$ -secretase inhibition did not affect melanocyte growth but inhibited melanoma proliferation *in vitro*, as well as melanoma tumorigenicity, in SCID mice (21). Our study focused on Notch1 because of its overexpression in melanomas; however, Notch2 and Notch4 transcripts were also increased in melanoma tissues and cell lines. Therefore, it is likely that other Notch receptors play a role in mediating the oncogenic effect of Notch1 signaling activation. Further studies will be useful in determining the contribution of the individual Notch receptors to melanocyte transformation and melanoma development.

In light of studies highlighting novel activating mutations in T-ALL (23), it might be expected that such mutations exist in melanomas as well. However, sequencing of a panel of 17 melanoma lines did not reveal any genetic alterations within the heterodimerization or PEST domains of Notch1 that have previously been shown to harbor activating mutations in 50% of human T-ALLs. In the absence of genetic mutations, another mechanism must exist to account for enhanced Notch signaling in human melanoma. We favor a scenario in which overexpression of Notch receptors in melanoma cells results in robust Notch signaling activation in human melanoma. Indeed, we observed significant up-regulation of Notch receptors 1, 2, and 4 at the mRNA level by real-time RT-PCR in melanoma cell lines and fresh melanoma specimens when compared with normal melanocytes. There are likely upstream factors that account for the increased transcriptional activity at the Notch receptor loci. One possibility was Ras, as it has been previously shown that oncogenic Ras activates Notch signaling and the wild-type Notch1 receptor is required to maintain the neoplastic phenotype of Ras-transformed cells (34). Studies performed in our laboratory, however, do not implicate mitogen-activated protein

kinase signaling in transcriptional regulation of Notch1, as inhibitors of both Raf and MEK were unable to abrogate expression of Notch1 (data not shown). Certainly, unraveling the mechanistic details responsible for Notch1 up-regulation in melanoma will be of immense value in the near future.

E-cadherin is the key adhesion molecule expressed by keratinocytes and melanocytes that permits keratinocytes to communicate with and exert regulatory control over melanocytic cellular processes (12, 15, 35). Loss of E-cadherin expression allows epidermal melanocytes to regulate their growth and adhesion independent of keratinocytes and is a key event in melanoma development (12, 15). Here, N<sup>IC</sup> down-regulated E-cadherin expression in melanocytes and also promoted robust up-regulation of MCAM, a cell adhesion molecule whose protein levels highly correlate with aggressive invasive behavior of melanoma cells *in vitro* and *in vivo* (17–19). Our data suggest that MCAM is a direct Notch target based on the identification of two high-affinity CSL binding sites within the MCAM promoter. We propose that, in early melanoma tumorigenesis, Notch activation results in MCAM expression and may ultimately contribute to melanoma progression. The significance of these data is underscored because loss of E-cadherin and up-regulation of MCAM are consistent with changes in gene expression that occur during the development of malignant melanoma.

There is only one report of active Notch1 protein acting alone to fully transform primary cells (9). Forced N<sup>IC</sup> expression in primary rat Schwann cells resulted in transformation and loss of Schwann cell differentiation markers. Active Notch1-induced transformation in rat kidney embryo cells; however, this was in cooperation with adenoviral protein E1A. Synergy of activated Notch1 and papillomavirus oncogenes E6 and E7 has also been reported in the transformation of immortalized epithelial cells (36). Whereas transformation of immortalized melanocytes subsequent to overexpression of a single oncogene has been reported (37, 38), full transformation of primary melanocytes, as defined by inducing tumorigenicity in animal models, generally requires disruption of several pathways, including Rb and p53 (39, 40). Oncogenic Ras is capable of promoting growth in soft agar as well as tumor formation in SCID mice in primary melanocytes but only in the presence of the SV40 early region (SV40ER), which encodes the viral large T and small T oncoproteins, and the catalytic subunit of the telomerase holoenzyme (39). Thus, although in our primary melanocyte cell lines N<sup>IC</sup> overexpression alone was capable of inducing a transformed phenotype *in vitro*, it is not alarming that N<sup>IC</sup>-infected cells failed to form tumors in NOD-SCID mice; therefore, Notch1 overexpression alone is not sufficient for full neoplastic transformation due to a lack of *in vivo* growth. However, our findings are nonetheless of significant importance in the consideration of signaling pathways that are deregulated and cooperate in the process of melanocyte transformation and melanoma development.

Our current studies strongly suggest that constitutive Notch signaling is associated with melanocyte transformation and melanoma tumorigenesis. Of particular significance is the ability of a  $\gamma$ -secretase inhibitor to selectively inhibit the growth of melanoma cell lines. These findings are consistent with a recent report identifying a  $\gamma$ -secretase inhibitor that induced effective apoptosis in human melanoma cells while sparing melanocytes (26). Multiple  $\gamma$ -secretase inhibitors have been developed and are presently in trials for use in the treatment of Alzheimer's patients (41). Based on the recent identification of activating Notch mutations in roughly 50% of human T-ALLs (23), therapies designed

to interfere with Notch activation, such as  $\gamma$ -secretase inhibitors, will undoubtedly be explored as a treatment option. Further extending the potential of Notch inhibitors for the treatment of human disease, these experiments suggest that targeting the Notch signaling may be a viable strategy in the therapy of melanoma.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Acknowledgments

Received 10/1/08; revised 4/9/09; accepted 4/30/09; published OnlineFirst 6/23/09.

**Grant support:** NIH grants CA76674, CA25874, CA10815, CA93372, CA47159, CA80999, CA098101, CA117881, and GM071695.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Drs. B. Keith and L. Brass for helpful discussions, J. Hayden for imaging assistance, Sherry Yang for assistance with Notch receptor real-time PCR experiments, and Gao Zhang for his expertise and aid in processing the microarray data.

## References

- Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. *Science* (New York) 1999;284:770-6.
- Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the *Drosophila* notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. *Cell* 1991;66:649-61.
- Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. Dynamics of notch expression during murine prostate development and tumorigenesis. *Cancer Res* 2001;61:7291-7.
- Raafat A, Bargo S, Anver MR, Callahan R. Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh). *Oncogene* 2004;23:9401-7.
- Sriuranpong V, Borges MW, Ravi RK, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. *Cancer Res* 2001;61:3200-5.
- Grynfeld A, Pahlman S, Axelson H. Induced neuroblastoma cell differentiation, associated with transient HES-1 activity and reduced HASH-1 expression, is inhibited by Notch1. *Int J Cancer* 2000;88:401-10.
- Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. *Proc Natl Acad Sci U S A* 1995;92:6414-8.
- Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, Foreman KE.  $\gamma$  secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. *Oncogene* 2005;24:6333-44.
- Li Y, Rao PK, Wen R, et al. Notch and Schwann cell transformation. *Oncogene* 2004;23:1146-52.
- Capobianco AJ, Zagouras P, Blaumueller CM, Artavanis-Tsakonas S, Bishop JM. Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. *Mol Cell Biol* 1997;17:6265-73.
- Hsu MY, Wheelock MJ, Johnson KR, Herlyn M. Shifts in cadherin profiles between human normal melanocytes and melanomas. *J Invest Dermatol Symp Proc* 1996;1:188-94.
- Tang A, Eller MS, Hara M, Yaar M, Hirohashi S, Gilchrist BA. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes *in vitro*. *J Cell Sci* 1994;107:983-92.
- Li G, Fukunaga M, Herlyn M. Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding  $\beta$ -catenin signaling. *Exp Cell Res* 2004;297:142-51.
- Li G, Schaidler H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. *Oncogene* 2001;20:8125-35.
- Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. *Am J Pathol* 2000;156:1515-25.
- Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmuller G, Johnson JP. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. *Cancer Res* 1987;47:841-5.
- Luca M, Hunt B, Bucana CD, Johnson JP, Fidler IJ, Bar-Eli M. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. *Melanoma Res* 1993;3:35-41.
- Xie S, Luca M, Huang S, et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. *Cancer Res* 1997;57:2295-303.
- Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. *Cancer Metastasis Rev* 1999;18:345-57.
- Schlagbauer-Wadl H, Jansen B, Muller M, et al. Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice. *Int J Cancer* 1999;81:951-5.
- Balint K, Xiao M, Pinnix CC, et al. Activation of Notch1 signaling is required for  $\beta$ -catenin-mediated human primary melanoma progression. *J Clin Invest* 2005;115:3166-76.
- Hoek K, Rimm DL, Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. *Cancer Res* 2004;64:5270-82.
- Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science* (New York) 2004;306:269-71.
- Liu ZJ, Xiao M, Balint K, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. *Cancer Res* 2006;66:4182-90.
- Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. *Cancer Res* 2001;61:3819-25.
- Qin JZ, Stennett L, Bacon P, et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. *Mol Cancer Ther* 2004;3:895-902.
- Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. *Blood* 2002;99:3398-403.
- Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). *Mol Cell Biol* 2001;21:5925-34.
- Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells *in vivo* and *in vitro*: vasculogenic mimicry. *Am J Pathol* 1999;155:739-52.
- Tun T, Hamaguchi Y, Matsunami N, Furukawa T, Honjo T, Kawauchi M. Recognition sequence of a highly conserved DNA binding protein RBP-J  $\kappa$ . *Nucleic Acids Res* 1994;22:965-71.
- Rangarajan A, Talora C, Okuyama R, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. *EMBO J* 2001;20:3427-36.
- Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signaling downstream of activated mammalian Notch. *Nature* 1995;377:355-8.
- Sarmiento LM, Huang H, Limon A, et al. Notch1 modulates timing of G<sub>1</sub>-S progression by inducing SKP2 transcription and p27 Kip1 degradation. *J Exp Med* 2005;202:157-68.
- Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. *Nat Med* 2002;8:979-86.
- Furukawa F, Fujii K, Horiguchi Y, et al. Roles of E- and P-cadherin in the human skin. *Microsc Res Tech* 1997;38:343-52.
- Rangarajan A, Syal R, Selvarajah S, Chakrabarti O, Sarin A, Krishna S. Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt. *Virology* 2001;286:23-30.
- Dotto GP, Moellmann G, Ghosh S, Edwards M, Halaban R. Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment. *J Cell Biol* 1989;109:3115-28.
- Wilson RE, Dooley TP, Hart IR. Induction of tumorigenicity and lack of *in vitro* growth requirement for 12-O-tetradecanoylphorbol-13-acetate by transfection of murine melanocytes with v-Ha-ras. *Cancer Res* 1989;49:711-6.
- Gupta PB, Kuperwasser C, Brunet JP, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. *Nat Genet* 2005;37:1047-54.
- Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* 2005;436:117-22.
- Citron M. Strategies for disease modification in Alzheimer's disease. *Nat Rev Neurosci* 2004;5:677-85.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes

Chelsea C. Pinnix, John T. Lee, Zhao-Jun Liu, et al.

*Cancer Res* 2009;69:5312-5320. Published OnlineFirst June 23, 2009.

<b>Updated version</b>	Access the most recent version of this article at: doi: <a href="https://doi.org/10.1158/0008-5472.CAN-08-3767">10.1158/0008-5472.CAN-08-3767</a>
<b>Supplementary Material</b>	Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2009/06/15/0008-5472.CAN-08-3767.DC1">http://cancerres.aacrjournals.org/content/suppl/2009/06/15/0008-5472.CAN-08-3767.DC1</a>

<b>Cited articles</b>	This article cites 41 articles, 17 of which you can access for free at: <a href="http://cancerres.aacrjournals.org/content/69/13/5312.full#ref-list-1">http://cancerres.aacrjournals.org/content/69/13/5312.full#ref-list-1</a>
<b>Citing articles</b>	This article has been cited by 9 HighWire-hosted articles. Access the articles at: <a href="http://cancerres.aacrjournals.org/content/69/13/5312.full#related-urls">http://cancerres.aacrjournals.org/content/69/13/5312.full#related-urls</a>

<b>E-mail alerts</b>	<a href="#">Sign up to receive free email-alerts</a> related to this article or journal.
<b>Reprints and Subscriptions</b>	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a> .
<b>Permissions</b>	To request permission to re-use all or part of this article, use this link <a href="http://cancerres.aacrjournals.org/content/69/13/5312">http://cancerres.aacrjournals.org/content/69/13/5312</a> . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.